

6 June 2025

**Cizzle Biotechnology Holdings plc**  
("Cizzle Biotechnology", or the "Company")

**Notice of Annual General Meeting and Posting of Annual Report**

Cizzle Biotechnology, the UK based diagnostics developer, announces that the notice of Annual General Meeting ("AGM") will be posted to shareholders today, along with the Company's Annual Report and Financial Statements for the year ended 31 December 2024 and will shortly be available for viewing on the Company's website at <https://cizzlebiotechnology.com>

The AGM will be held at 11.00 a.m. on 30 June 2025 at the offices of Shakespeare Martineau LLP, 6<sup>th</sup> Floor, 60 Gracechurch Street, London, EC3V 0HR.

**Enquiries:**

**Cizzle Biotechnology Holdings plc**  
Allan Syms (Executive Chairman)

Via IFC Advisory

**Allenby Capital Limited**  
John Depasquale / Piers Shimwell (Corporate Finance)  
Stefano Aquilino / Amrit Nahal (Sales and Corporate Broking)

+44(0) 20 3328 5656

**IFC Advisory Limited**  
Tim Metcalfe  
Florence Chandler

+44(0) 20 3934 6630

**About Cizzle Biotechnology**

Based on the pioneering work of Professor Coverley and colleagues, on a naturally occurring variant of the cell nuclear protein CIZ1, the CIZ1B biomarker is highly associated with the presence of early-stage cancer. The company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer and has now entered commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care. Cizzle was admitted to the Standard segment of the main market of the London Stock Exchange in May 2021.

For more information, please see <https://cizzlebiotechnology.com>

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOASSFSUMEISELM